GSK, Teva Say Lamictal IP Licensing Deal Wasn't Conspiracy

Law360, Washington (August 16, 2012, 1:35 PM EDT) -- GlaxoSmithKline LLC and Teva Pharmaceuticals USA Inc. urged a New Jersey federal judge on Wednesday to dismiss a putative class action that accuses them of conspiring to keep a generic epilepsy drug off the market, saying the licensing agreement relating to GSK's patent exclusivity is protected by law from antitrust litigation.

GSK and Teva reached a patent dispute settlement in 2005 that allowed the generic-drug maker to sell versions of GSK's Lamictal before the company lost exclusivity rights to the epilepsy treatment, but drug distributors Louisiana...
To view the full article, register now.